Advanced Solid Tumors
Conditions
Interventions
Single arm, BMS-986504 Specified dose on specified days
Sponsors
Hreiki Joseph
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Participants must have histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue. Participants must have unresectable or metastatic disease not amenable to curative therapies after progression on prior therapies at the time of enrollment. Participants must have Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Participants must have presence of at least one measurable tumor lesion per RECIST 1.1 at baseline.
Exclusion criteria
Exclusion criteria: Participants must not have prior treatment with a Protein arginine methyltransferase 5 (PRMT5) or Methionine adenosyltransferase 2A (MAT2A) inhibitor. Participants must not have active brain metastases or carcinomatous meningitis. Participants must not have a history of gastrointestinal disease or other gastrointestinal conditions (e.g., uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications. Participants must not have known severe hypersensitivity to study treatment and/or any of its excipients. Other protocol-defined Inclusion/Exclusion criteria apply.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Plasma Concentration (Cmax) of BMS-986504 | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of Participants With Dose-limiting Toxicities (DLTs) | — |
Countries
China, Japan
Contacts
Public ContactJoseph Hreiki
Bristol-Myers Squibb
Outcome results
None listed